879502-52-0

Basic information

• Product Name: (R)-tert-Butoxycarbonylamino-[4-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-acetic acid
• Synonyms: (R)-tert-Butoxycarbonylamino-[4-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-acetic acid
• CAS NO: 879502-52-0
• Molecular Weight: 381.426
• Mol File: 879502-52-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (R)-tert-Butoxycarbonylamino-[4-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-Butoxycarbonylamino-[4-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-acetic acid(879502-52-0)
• EPA Substance Registry System: (R)-tert-Butoxycarbonylamino-[4-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-acetic acid(879502-52-0)

Safety Data

• Hazardous Substances Data: 879502-52-0(Hazardous Substances Data)

Upstream product

• 947183-05-3 2,5-dichloro-benzenesulfonic acid (R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 
• 27460-85-1 N-(tert-butoxycarbonyl)-D-(4-hydroxyphenyl)glycine 
• 83461-40-9 methanesulfonic acid (R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 

Downstream Products

• 879502-54-2 2-((S)-2-{(R)-2-tert-butoxycarbonylamino-2-[4-((S)-2,2-dimethyl-[1,3]dioxolan4-ylmethoxy)phenyl]acetylamino}-3-phenylpropionylamino)thiazole-4-carboxylic acid methyl ester 

Relevant articles and documents

METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS

Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.

Substituted hydantoins

The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.